Volume 9, Issue 4 (Vol.9 No.4 Jan 2021)                   rbmb.net 2021, 9(4): 394-398 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Masoumi E, Mirzaei A, Ghaffari-Nazari H, Tahaghoghi-Hajghorbani S, jalali S A, Tavakkol-Afshari* J. Serum Levels of Soluble Fas and Fas Ligand in Iranian Women with Pre-eclampsia. rbmb.net 2021; 9 (4) :394-398
URL: http://rbmb.net/article-1-524-en.html
Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:   (3615 Views)
Background: The precise responsible mechanism of pre-eclampsia remains controversial however, recent data suggest a main role of the abnormal activation of the adaptive immune system and Apoptosis. In this study, we have measured serum levels of Fas/Fasl as two important members of extrinsic apoptotic pathway in patient with pre-eclampsia.

Methods: 207 participants including 99 pre-eclampsia patients and 108 age and sex-matched normal pregnant women were involved in the case-control study. Plasma sample from each participant was collected and stored at –20 ̊C until batch processing.
Serum levels of Fas and Fas ligand were measured by ELISA for each participant including 99 pre-eclampsia patients and 108 normal pregnant women. Following a test of statistical normality, nonparametric data were analyzed by Mann-Whitney.

Results: sFas levels in case group was significantly higher than controls; 584 (397-892) pg/ml in cases opposed to 341 (213-602) pg/ml in controls (p value< 0.01). sFasL in pre-eclampsia women was a little lower than controls; 255 (173-318) pg/ml and in case group compared to 265.5 (184-381.5) pg/ml in controls.

Conclusions: We have found the increased levels of sFas in patients with pre-eclampsia in compare with the healthy pregnant women. It seems that abnormality in sFAS is related with pre-eclampsia.
Full-Text [PDF 156 kb]   (1368 Downloads)    
Type of Article: Original Article | Subject: Immunology
Received: 2020/07/7 | Accepted: 2020/07/19 | Published: 2021/03/8

1. Ciarmela P, Boschi S, Bloise E, Marozio L, Benedetto C, Castellucci M, et al. Polymorphisms of FAS and FAS ligand genes in preeclamptic women. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2010;148(2):144-146. [DOI:10.1016/j.ejogrb.2009.10.026] [PMID]
2. DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol. 1999;155(1):293-301. [DOI:10.1016/S0002-9440(10)65123-1]
3. Moffett A, Hiby S. How does the maternal immune system contribute to the development of pre-eclampsia? Placenta. 2007;28:S51-S56. [DOI:10.1016/j.placenta.2006.11.008] [PMID]
4. Kwak‐Kim J, Chung‐Bang H, Ng S, Ntrivalas E, Mangubat C, Beaman K, et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Human Reproduction. 2003;18(4):767-773. [DOI:10.1093/humrep/deg156] [PMID]
5. Masoumi E, Tavakkol‐Afshari J, Nikpoor AR, Ghaffari‐Nazari H, Tahaghoghi‐hajghorbani S, Jalali SA. Relationship between Fas and Fas Ligand gene polymorphisms and pre‐eclampsia. J Obstet Gynaecol Res. 2016;42(10):1272-1278. [DOI:10.1111/jog.13062] [PMID]
6. Roh C-R, Lee J-W, Kang B-H, Yang S-H, Kim B-G, Bae D-S, et al. Differential expressions of Fas and Fas ligand in human placenta. J Korean Med Sci. 2002;17(2):213-216. [DOI:10.3346/jkms.2002.17.2.213] [PMID] [PMCID]
7. Mor G, Gutierrez LS, Eliza M, Kahyaoglu F, Arici A. Fas‐fas ligand system‐induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol. 1998;40(2):89-94. [DOI:10.1111/j.1600-0897.1998.tb00396.x] [PMID]
8. Jalali SA, Shandiz FH, Afshari JT, Ghochan MDT, Nikpoor AR, Mohammadi M. Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN. Reports of biochemistry & molecular biology. 2018;7(1):23-29.
9. Nagata S. Fas and Fas ligand: a death factor and its receptor. Advances in immunology. 1994;57:135-144. [DOI:10.1016/S0065-2776(08)60672-0]
10. Uckan D, Steele A, Wang B, Chamizo W, Koutsonikolis A, Gilbert-Barness E, et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod. 1997;3(8):655-62. [DOI:10.1093/molehr/3.8.655] [PMID]
11. Li N-L, Nie H, Yu Q-W, Zhang J-Y, Ma A-L, Shen B-H, et al. Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol. 2004;10(21):3151-3156. [DOI:10.3748/wjg.v10.i21.3151] [PMID] [PMCID]
12. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol. 1994;6(10):1545-53. [DOI:10.1093/intimm/6.10.1545] [PMID]
13. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol today. 1993;14(7):353-6. [DOI:10.1016/0167-5699(93)90235-D]
14. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol. 2000;18(1):367-91. [DOI:10.1146/annurev.immunol.18.1.367] [PMID]
15. Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD. Soluble Fas and Fas ligand in pregnancy: influence of hypertension. Angiology. 2012;63(1):35-8. [DOI:10.1177/0003319711406901] [PMID]
16. Kuntz TB, Christensen RD, Stegner J, Duff P, Koenig JM. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia. Pediatr Res. 2001;50(6):743-9. [DOI:10.1203/00006450-200112000-00019] [PMID]
17. Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. The expression and concentrations of Fas/APO-1 (CD95) antigen in patients with severe pre-eclampsia. J Reprod Immunol. 2001;49(2):153-64. [DOI:10.1016/S0165-0378(00)00086-3]
18. Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1-and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1999;86(2):165-170. [DOI:10.1016/S0301-2115(99)00065-2]
19. Laskowska M, Laskowska K, Leszczyńska-Gorzelak B, Oleszczuk J. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2006;126(2):155-159. [DOI:10.1016/j.ejogrb.2005.08.015] [PMID]
20. Hsu C-D, Harirah H, Basherra H, Mor G. Serum soluble Fas levels in preeclampsia. Obstetrics & Gynecology. 2001;97(4):530-532. https://doi.org/10.1097/00006250-200104000-00010 [DOI:10.1016/S0029-7844(00)01227-8]
21. Bayram M, Taskaya A, Bagriacik EU, Ilhan MN, Yaman M. The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia. J Matern Fetal Neonatal Med. 2012. [DOI:10.3109/14767058.2012.722710] [PMID]
22. Hu W, Wang Z, Dong M, Wang H. Expression of Fas and FasL in serum and placenta of preeclamptic pregnancy and its significance. Zhejiang da xue xue bao Yi xue ban. 2005;34(6):499-502.
23. Enjoji M, Yamaguchi K, Nakashima M, Ohta S, Kotoh K, Fukushima M, et al. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Liver International. 2004;24(4):330-334. [DOI:10.1111/j.1478-3231.2004.0931.x] [PMID]
24. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, et al. Unequal death in T helper cell (Th) 1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med. 1997;185(10):1837-49. [DOI:10.1084/jem.185.10.1837] [PMID] [PMCID]
25. Musiał K, Zwolińska D. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis. 2011;16(7):653-9. [DOI:10.1007/s10495-011-0604-2] [PMID] [PMCID]
26. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol. 2003;59(2):161-73. [DOI:10.1016/S0165-0378(03)00045-7]
27. Hoshimoto K, Hayashi M, Ohkura T. Plasma levels of soluble Fas during normal pregnancy. Gynecol Obstet Invest. 2001;51(2):96-8. [DOI:10.1159/000052901] [PMID]
28. Kim S, Kim JY, Lee TH, Suk K, Cha H-S, Koh E-M, et al. Soluble Fas ligand-susceptible" memory" cells in mice but not in human: potential role of soluble Fas ligand in deletion of auto-reactive cells. Autoimmunity. 2002;35(1):15-20. [DOI:10.1080/08916930290005882] [PMID]
29. Abrahams VM, Straszewski‐Chavez SL, Guller S, Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod. 2004;10(1):55-63. [DOI:10.1093/molehr/gah006] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb